Innate Pharma initiates IPH43 program to develop «first-in-class» anti-MICA antibody

• MICA validated as a novel target for antibody drug development in solid tumors
• IPH43 program now aims at selection and optimization of the best development candidate

Innate Pharma SA (the “Company” - Euronext Paris: FR0010331421 – IPH), the innate immunity company developing first-in-class drug candidates for cancer and inflammatory diseases, announces the initiation of a new program to develop an anti-MICA therapeutic antibody in oncology. The program, named IPH43, is the newest to emerge from Innate Pharma’s discovery platform.

MICA is a highly polymorphic ligand of the NK cell activating receptor NKG2D. MICA is specifically expressed on several highly prevalent solid tumors including breast, colorectal and lung. Innate Pharma has generated a panel of high affinity antibodies recognizing all forms of MICA which is now being tested and optimized to select the best development candidate.